Table 5.
Primary and secondary outcomes
| Overall | Center A | Center B | p value | |
|---|---|---|---|---|
| Screening completeness | ||||
| HPV-negative women, the results given | 247/249 (99.2) | 127/128 (99.2) | 120/121 (99.2) | 1 |
| HPV-positive women, VIA done and negative | 49/55 (89.1) | 21/25 (84.0) | 28/30 (93.3) | 0.56 |
| HPV-positive women, VIA positive and treatment provided | 3/6 (50.0) | 2/4 (50.0) | 1/2 (50.0) | 1 |
| Women with complete screening sequencea | 299/317 (94.3) | 150/160 (93.8) | 149/157 (94.9) | 0.84 |
| Women satisfaction (high vs low)b | ||||
| Postsampling | 205/317 (64.7) | 128/160 (80.0) | 77/157 (49.0) | < 0.001 |
| Postresults | 300/315 (94.6) | 146/158 (91.2) | 154/157 (98.1) | 0.014 |
| Post-VIA | 38/55 (69.1) | 15/25 (60.0) | 23/30 (76.7) | 0.29 |
Data are number of women (%)
aScreening sequence was considered complete when an HPV-negative woman was informed of the result of the HPV test, when an HPV-positive woman had a subsequent negative VIA test, or when an HPV-positive woman with a subsequent positive VIA test had an appropriate treatment
bSatisfaction was assessed at three steps: after vaginal sampling (postsampling); after women received their test results (postresults); and after the visual inspection if relevant (post-VIA)